Viking Therapeutics (VKTX) Gains from Sales and Divestitures (2014 - 2026)

Viking Therapeutics has disclosed Gains from Sales and Divestitures across 13 years of filings, most recently posting $30211.0 for Q1 2026.

• Gains from Sales and Divestitures for Q1 2026 came in at $30211.0, down 95.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $30211.0 (down 95.48% YoY), and the FY2025 annual result was $854220.0, changed N/A from the prior year.
• Gains from Sales and Divestitures came in at $30211.0 for Q1 2026 at Viking Therapeutics, down from $854220.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $1.6 million in Q3 2024 to a low of $30211.0 in Q1 2026.
• The 5-year median for Gains from Sales and Divestitures is $668015.0 (2025), against an average of $633221.8.
• Across the five-year window, Gains from Sales and Divestitures jumped 262.76% in 2024 and sank 95.99% in 2025, its largest moves.
• Viking Therapeutics' Gains from Sales and Divestitures stood at $409569.0 in 2022, then jumped by 91.69% to $785105.0 in 2023, then soared by 97.55% to $1.6 million in 2024, then plunged by 44.92% to $854220.0 in 2025, then sank by 96.46% to $30211.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $30211.0 (Q1 2026), $854220.0 (Q4 2025), and $62252.0 (Q3 2025), per Business Quant data.